ExodusPoint Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

ExodusPoint Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,669	Closed	-$103K	–	3020
2021 Q1	$103K	Buy	+12,669	New	+$138K	﹤0.01%	1976
2020 Q3	–	Sell	-10,036	Closed	-$75K	–	2388
2020 Q2	$75K	Buy	+10,036	New	+$67.3K	﹤0.01%	1659

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's KLDO Position: Q2 2021 in Review

ExodusPoint Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2021, closing a stake of 12,669 shares — an estimated $103K sold.

ExodusPoint Capital Management first reported a position in KLDO in Q2 2020 and held it in 2 quarters. The position peaked at $103K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q2 2021.

ExodusPoint Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
ExodusPoint Capital Management sold 12,669 Kaleido Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $103K.
ExodusPoint Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
ExodusPoint Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $103K in Q1 2021.
71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2021.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.